Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Ethical committee approval has been obtained from Ethics committee of Faculty of Medicine, Alexandria University.
- Agreement from all participants should be taken in this clinical study by assigning an informed consent.
- Nephrotic diseased patients,will be recruited from Alexandria main university hospital (AMUH).
- The 74 participants will be non-randomly assigned into 2 groups.
- The control group is non-obese nephrotic patients with BMI <25 kg/m2 will receive receive Cyclosporine capsule with conventional initial dose 3 mg/kg/day using actual weight.
- The Case interventional group is Obese nephrotic patients with BMI> 25kg/m2 will receive Cyclosporine capsule with the best weight based dose to achieve the targeted therapeutic trough level and targeted urinary protein/ creatinine ratio.
All patients will be subjected to :
- First visit: Full patient history, anthropometrics (weight, hight, BMI, fat %, water %, muscles% and clinical examination. Calculate the initial cyclosporine dose 3mg/kg/day in 2 divided doses based on actual weight.
- Second visit after one month: blood sample withdrawal for measuring trough level, lipid profile and thyroid profile, urinary sample to measure uPCR If patients don't reach to targeted therapeutic trough level and targeted urinary protein/ creatinine ratio,re-modifying the dose and repeat the labs after another one month in third visit.
- Finally find the best weight can be used to achieve the targeted therapeutic trough level and targeted urinary protein/ creatinine ratio, and its relation with fat content and lipid profile
- The appropriate Statistical tests will be hold according to study design and parameters (parametric and non-parametric) to evaluate the significance of the results.
- Results, conclusion, discussion and recommendations will be given.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Enas A Mohamed, PharmD
- Phone Number: +2 01004344021
- Email: gs-enas.elkady@alexu.edu.eg
Study Contact Backup
- Name: Noha A Hamdy, PhD
- Phone Number: +2 01005182151
- Email: noha.alaaeldine@alexu.edu.eg
Study Locations
-
-
-
Alexandria, Egypt
- Recruiting
- Alexandria University
-
Principal Investigator:
- Noha A Hamdy, PhD
-
Contact:
- Noha A Hamdy, PhD
- Phone Number: +2 01005182151
- Email: noha.alaaeldine@alexu.edu.eg
-
Contact:
- Yasmin S Naga, PhD
- Phone Number: +2 01222244673
- Email: yasminenaga@gmail.com
-
Principal Investigator:
- Hanan M El-Goweilli, PhD
-
Principal Investigator:
- Yasmin S Naga, PhD
-
Principal Investigator:
- Enas A Mohamed, Pharm-D
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Obese and overweight Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (BMI>25 kg/m2)
- Normal or underweight individuals Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (serving as control group)
Exclusion Criteria:
- Hepatic patients liver cirrhosis (moderate to severe liver impairment)
- Cancer patients,
- Pregnant and lactating female patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Obese nephrotic patients with BMI>25 kg/m2
Nephrotic obese patients receive Cyclosporine capsule initially according to weight-based dose then modifying the dose according to targeted therapeutic level. To determine the best weight can be used to get the targeted therapeutic level. Correlate with the lipid profile, fat percentage and other anthropometric measures. |
Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
|
|
Other: Non obese nephrotic patients with BMI<25 kg/m2
Nephrotic non-obese patients receive Cyclosporine capsule initially according to weight-based dose then modified dose according to targeted therapeutic level.
|
Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cyclosporine level concentration and its correlation to anthropometric measures
Time Frame: 1 month
|
Measuring of Cyclosporine level in whole blood after one month of starting the drug
|
1 month
|
|
Determine a suitable weight-based dose for obese patients
Time Frame: 1 month
|
Modifying the Cyclosporine dose according to measured trough level
|
1 month
|
|
Measuring the weight as one of anthropometric measures
Time Frame: Day 1
|
Measuring anthropometric measures as; weight in kilograms at base line of starting the Cyclosporine regimen.
|
Day 1
|
|
Measuring the height as one of anthropometric measures
Time Frame: Day 1
|
Measuring anthropometric measures as;height in metres at base line of starting the Cyclosporine regimen.
|
Day 1
|
|
Measuring the BMI as one of anthropometric measures
Time Frame: Day 1
|
Measuring anthropometric measures as; BMI (body mass index) in kilograms/meter^2 at base line of starting the Cyclosporine regimen.
|
Day 1
|
|
Measuring some of important in-body anthropometric measures
Time Frame: Day 1
|
Measuring anthropometric measures as;body fat percentage, body water percentage and muscle percentage content at base line of starting the Cyclosporine regimen.
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of kidney functions
Time Frame: 1 month
|
Measuring parameters represent the kidney functions including (serum creatinine in mg/dl.)
|
1 month
|
|
Assessment of kidney functions as clearance estimation
Time Frame: 1 month
|
Measuring parameters represent the kidney functions including (estimated GFR in mL/min/1.73
m²)
|
1 month
|
|
Assessment of kidney functions as urinary protein release
Time Frame: 1 month
|
Measuring parameters represent the kidney functions including (Urinary protein-creatinine ratio in gm/gm)
|
1 month
|
|
Lipid profile assessment
Time Frame: 1 month
|
Measuring lipid profile including (HDL, LDL,VLDL and TG) in mg/dl.
|
1 month
|
|
Thyroid function assessment
Time Frame: 1 month
|
Measuring Thyroid profile including (TSH, fT3, fT4 ).
|
1 month
|
|
Covid-19 vaccine status assessment
Time Frame: Day 1
|
Assess if the patient received Covid-19 vaccine, or not.
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Syndrome
- Nephrotic Syndrome
- Nephrosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
Other Study ID Numbers
- 0107113
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.